[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fkfrvKjjsxep-W0b7kkWbSU5vBssDOM_Q-IX1RbbVQwQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Helsinn Healthcare SA",[4],32,false,1,13,8495,3,5,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Chemotherapy-Induced Nausea and Vomiting",6,{"name":18,"count":11},"Healthy Volunteers",{"name":20,"count":21},"Postoperative Nausea and Vomiting",2,{"name":23,"count":21},"Chemotherapy-induced Nausea and Vomiting",{"name":25,"count":21},"Cachexia; Cancer",{"name":27,"count":21},"Non Small Cell Lung Cancer",{"name":29,"count":21},"Acute Myeloid Leukemia",{"name":31,"count":21},"Myelodysplastic Syndrome",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06904235","Study With IV NEPA (Fosnetupitant\u002FPalonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","2027-10","IV NEPA",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,73,91,109,136,154,172,273,360,417,451,473,495,517,535,553,577,595,613,639,657,679,697,715,751,769,796,814,839,857,875],{"intervention":37,"totalTrials":8,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":67,"PHASE4":69,"NA":71},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":8,"soonestReadout":36},[55],{"nctId":34,"briefTitle":35,"status":56,"phases":57,"primaryCompletion":36,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":64},"RECRUITING",[41],"2027-12","2025-07-07",95,[62,63],"Nausea and Vomiting Chemotherapy-Induced","Nausea Post Chemotherapy",[37,65,66],"Reference Treatment: IV ondansetron","Reference Treatment: IV fosaprepitant",{"trials":68,"activeCount":50},[],{"trials":70,"activeCount":50},[],{"trials":72,"activeCount":50},[],{"intervention":65,"totalTrials":8,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":76,"activeCount":50},[],{"trials":78,"activeCount":50},[],{"trials":80,"activeCount":8,"soonestReadout":36},[81],{"nctId":34,"briefTitle":35,"status":56,"phases":82,"primaryCompletion":36,"completion":58,"start":59,"enrollment":60,"conditions":83,"interventions":84},[41],[62,63],[37,65,66],{"trials":86,"activeCount":50},[],{"trials":88,"activeCount":50},[],{"trials":90,"activeCount":50},[],{"intervention":66,"totalTrials":8,"cells":92},{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":103,"PHASE4":105,"NA":107},{"trials":94,"activeCount":50},[],{"trials":96,"activeCount":50},[],{"trials":98,"activeCount":8,"soonestReadout":36},[99],{"nctId":34,"briefTitle":35,"status":56,"phases":100,"primaryCompletion":36,"completion":58,"start":59,"enrollment":60,"conditions":101,"interventions":102},[41],[62,63],[37,65,66],{"trials":104,"activeCount":50},[],{"trials":106,"activeCount":50},[],{"trials":108,"activeCount":50},[],{"intervention":110,"totalTrials":8,"cells":111},"NEPA",{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":118,"PHASE4":120,"NA":134},{"trials":113,"activeCount":50},[],{"trials":115,"activeCount":50},[],{"trials":117,"activeCount":50},[],{"trials":119,"activeCount":50},[],{"trials":121,"activeCount":50},[122],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},"NCT04817189","Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","COMPLETED",[43],"2024-07-02","2021-02-01",414,[23],[110,132,133],"Granisetron, 2 mg","Dexamethasone, 8 mg (oral) or equivalent IV dose",{"trials":135,"activeCount":50},[],{"intervention":132,"totalTrials":8,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":152},{"trials":139,"activeCount":50},[],{"trials":141,"activeCount":50},[],{"trials":143,"activeCount":50},[],{"trials":145,"activeCount":50},[],{"trials":147,"activeCount":50},[148],{"nctId":123,"briefTitle":124,"status":125,"phases":149,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":150,"interventions":151},[43],[23],[110,132,133],{"trials":153,"activeCount":50},[],{"intervention":133,"totalTrials":8,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":170},{"trials":157,"activeCount":50},[],{"trials":159,"activeCount":50},[],{"trials":161,"activeCount":50},[],{"trials":163,"activeCount":50},[],{"trials":165,"activeCount":50},[166],{"nctId":123,"briefTitle":124,"status":125,"phases":167,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":168,"interventions":169},[43],[23],[110,132,133],{"trials":171,"activeCount":50},[],{"intervention":173,"totalTrials":174,"cells":175},"Pracinostat",8,{"EARLY_PHASE1":176,"PHASE1":190,"PHASE2":212,"PHASE3":257,"PHASE4":269,"NA":271},{"trials":177,"activeCount":50},[178],{"nctId":179,"briefTitle":180,"status":125,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":188},"NCT02058784","Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects",[39],"2014-03","2014-02",28,[18,186,187],"Moderate to Heavy Smokers","Non-smokers",[189],"pracinostat",{"trials":191,"activeCount":50},[192,201],{"nctId":193,"briefTitle":194,"status":125,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":16,"conditions":198,"interventions":200},"NCT03495934","A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body",[40],"2018-02-28","2018-02-08",[199],"Healthy Subjects",[189],{"nctId":202,"briefTitle":203,"status":125,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":6,"conditions":208,"interventions":209},"NCT02118909","Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects",[40],"2014-06","2014-08","2014-05",[18,187],[173,210,211],"Itraconazole","Ciprofloxacin",{"trials":213,"activeCount":50},[214,227,238,248],{"nctId":215,"briefTitle":216,"status":125,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT01993641","Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA",[41],"2015-05","2016-06","2013-12",45,[31,223],"MDS",[189,225,226],"Azacitidine","Decitabine",{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT03151304","A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes","TERMINATED",[41],"2020-12-01","2017-06-01",64,[236],"Myelodysplastic Syndromes",[173,225],{"nctId":239,"briefTitle":240,"status":125,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":247},"NCT01873703","Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome",[41],"2015-11","2016-11","2013-06",102,[31],[189,225],{"nctId":249,"briefTitle":250,"status":125,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT01912274","Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)",[41],"2016-11-08","2013-12-24",50,[29],[173,225],{"trials":258,"activeCount":50},[259],{"nctId":260,"briefTitle":261,"status":230,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":267},"NCT03151408","An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia",[42],"2020-08-20","2017-06-23",406,[29],[173,268,225],"Placebos",{"trials":270,"activeCount":50},[],{"trials":272,"activeCount":50},[],{"intervention":274,"totalTrials":275,"cells":276},"Palonosetron",7,{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":294,"PHASE4":356,"NA":358},{"trials":278,"activeCount":50},[],{"trials":280,"activeCount":50},[],{"trials":282,"activeCount":50},[283],{"nctId":284,"briefTitle":285,"status":125,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT03204279","PK\u002FPD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting",[41],"2019-09-30","2017-08-31",67,[291],"Chemotherapy-induced Nausea and Vomiting (CINV)",[293,274,293,274],"Netupitant",{"trials":295,"activeCount":50},[296,308,319,329,339,348],{"nctId":297,"briefTitle":298,"status":125,"phases":299,"primaryCompletion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT01376297","A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting",[42],"2012-09","2011-07",413,[15],[305,306,274,307],"Netupitant and Palonosetron","Aprepitant","Dexamethasone",{"nctId":309,"briefTitle":310,"status":125,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":317},"NCT00828295","Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients",[42],"2008-12","2009-01","2008-08",150,[20],[318,318],"palonosetron",{"nctId":320,"briefTitle":310,"status":125,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT01395901",[42],"2012-03","2012-04","2011-06",670,[20],[274,328],"Ondansetron",{"nctId":330,"briefTitle":331,"status":125,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT01442376","Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients",[42],"2012-10","2012-11","2011-09",502,[15],[274,274,328],{"nctId":340,"briefTitle":341,"status":125,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT02557035","An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting",[42],"2016-03","2015-10",441,[15],[274,307],{"nctId":349,"briefTitle":350,"status":125,"phases":351,"primaryCompletion":334,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT01339260","An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting",[42],"2011-04",1455,[15],[305,274,307],{"trials":357,"activeCount":50},[],{"trials":359,"activeCount":50},[],{"intervention":307,"totalTrials":16,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":413,"NA":415},{"trials":363,"activeCount":50},[],{"trials":365,"activeCount":50},[],{"trials":367,"activeCount":50},[],{"trials":369,"activeCount":50},[370,374,386,396,400,404],{"nctId":297,"briefTitle":298,"status":125,"phases":371,"primaryCompletion":300,"start":301,"enrollment":302,"conditions":372,"interventions":373},[42],[15],[305,306,274,307],{"nctId":375,"briefTitle":376,"status":125,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":382},"NCT03403712","A Study to Assess the Safety and the Efficacy of IV Fosnetupitant\u002FPalonosetron (260 mg\u002F0.25 mg) Combination Compared to Oral Netupitant\u002FPalonosetron (300 mg\u002F0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer",[42],"2018-09-19","2018-03-16",404,[23],[383,384,385],"fosnetupitant\u002F palonosetron","netupitant\u002Fpalonosetron","dexamethasone",{"nctId":387,"briefTitle":388,"status":125,"phases":389,"primaryCompletion":390,"completion":390,"start":242,"enrollment":391,"conditions":392,"interventions":393},"NCT02517021","A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting",[42],"2016-08",405,[15],[394,395,307],"Pro-netupitant\u002FPalonosetron","Netupitant\u002FPalonosetron",{"nctId":340,"briefTitle":341,"status":125,"phases":397,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":398,"interventions":399},[42],[15],[274,307],{"nctId":349,"briefTitle":350,"status":125,"phases":401,"primaryCompletion":334,"start":352,"enrollment":353,"conditions":402,"interventions":403},[42],[15],[305,274,307],{"nctId":405,"briefTitle":406,"status":125,"phases":407,"primaryCompletion":334,"completion":334,"start":301,"enrollment":408,"conditions":409,"interventions":410},"NCT01363479","An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting",[42],743,[15],[411,412,307],"Oral palonosetron","I.V. palonosetron",{"trials":414,"activeCount":50},[],{"trials":416,"activeCount":50},[],{"intervention":225,"totalTrials":12,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":441,"PHASE4":447,"NA":449},{"trials":420,"activeCount":50},[],{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[425,429,433,437],{"nctId":215,"briefTitle":216,"status":125,"phases":426,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":427,"interventions":428},[41],[31,223],[189,225,226],{"nctId":228,"briefTitle":229,"status":230,"phases":430,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":431,"interventions":432},[41],[236],[173,225],{"nctId":239,"briefTitle":240,"status":125,"phases":434,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":435,"interventions":436},[41],[31],[189,225],{"nctId":249,"briefTitle":250,"status":125,"phases":438,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":439,"interventions":440},[41],[29],[173,225],{"trials":442,"activeCount":50},[443],{"nctId":260,"briefTitle":261,"status":230,"phases":444,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":445,"interventions":446},[42],[29],[173,268,225],{"trials":448,"activeCount":50},[],{"trials":450,"activeCount":50},[],{"intervention":305,"totalTrials":21,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":469,"NA":471},{"trials":454,"activeCount":50},[],{"trials":456,"activeCount":50},[],{"trials":458,"activeCount":50},[],{"trials":460,"activeCount":50},[461,465],{"nctId":297,"briefTitle":298,"status":125,"phases":462,"primaryCompletion":300,"start":301,"enrollment":302,"conditions":463,"interventions":464},[42],[15],[305,306,274,307],{"nctId":349,"briefTitle":350,"status":125,"phases":466,"primaryCompletion":334,"start":352,"enrollment":353,"conditions":467,"interventions":468},[42],[15],[305,274,307],{"trials":470,"activeCount":50},[],{"trials":472,"activeCount":50},[],{"intervention":384,"totalTrials":21,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":491,"NA":493},{"trials":476,"activeCount":50},[],{"trials":478,"activeCount":50},[],{"trials":480,"activeCount":50},[],{"trials":482,"activeCount":50},[483,487],{"nctId":375,"briefTitle":376,"status":125,"phases":484,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":485,"interventions":486},[42],[23],[383,384,385],{"nctId":387,"briefTitle":388,"status":125,"phases":488,"primaryCompletion":390,"completion":390,"start":242,"enrollment":391,"conditions":489,"interventions":490},[42],[15],[394,395,307],{"trials":492,"activeCount":50},[],{"trials":494,"activeCount":50},[],{"intervention":328,"totalTrials":21,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":513,"NA":515},{"trials":498,"activeCount":50},[],{"trials":500,"activeCount":50},[],{"trials":502,"activeCount":50},[],{"trials":504,"activeCount":50},[505,509],{"nctId":320,"briefTitle":310,"status":125,"phases":506,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":507,"interventions":508},[42],[20],[274,328],{"nctId":330,"briefTitle":331,"status":125,"phases":510,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":511,"interventions":512},[42],[15],[274,274,328],{"trials":514,"activeCount":50},[],{"trials":516,"activeCount":50},[],{"intervention":306,"totalTrials":8,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":531,"NA":533},{"trials":520,"activeCount":50},[],{"trials":522,"activeCount":50},[],{"trials":524,"activeCount":50},[],{"trials":526,"activeCount":50},[527],{"nctId":297,"briefTitle":298,"status":125,"phases":528,"primaryCompletion":300,"start":301,"enrollment":302,"conditions":529,"interventions":530},[42],[15],[305,306,274,307],{"trials":532,"activeCount":50},[],{"trials":534,"activeCount":50},[],{"intervention":383,"totalTrials":8,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":549,"NA":551},{"trials":538,"activeCount":50},[],{"trials":540,"activeCount":50},[],{"trials":542,"activeCount":50},[],{"trials":544,"activeCount":50},[545],{"nctId":375,"briefTitle":376,"status":125,"phases":546,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":547,"interventions":548},[42],[23],[383,384,385],{"trials":550,"activeCount":50},[],{"trials":552,"activeCount":50},[],{"intervention":554,"totalTrials":8,"cells":555},"anamorelin HCl",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":573,"NA":575},{"trials":557,"activeCount":50},[],{"trials":559,"activeCount":50},[],{"trials":561,"activeCount":50},[],{"trials":563,"activeCount":50},[564],{"nctId":565,"briefTitle":566,"status":125,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT03743064","A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[42],"2022-12-27","2019-05-06",318,[25,27],[554],{"trials":574,"activeCount":50},[],{"trials":576,"activeCount":50},[],{"intervention":394,"totalTrials":8,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":591,"NA":593},{"trials":580,"activeCount":50},[],{"trials":582,"activeCount":50},[],{"trials":584,"activeCount":50},[],{"trials":586,"activeCount":50},[587],{"nctId":387,"briefTitle":388,"status":125,"phases":588,"primaryCompletion":390,"completion":390,"start":242,"enrollment":391,"conditions":589,"interventions":590},[42],[15],[394,395,307],{"trials":592,"activeCount":50},[],{"trials":594,"activeCount":50},[],{"intervention":268,"totalTrials":8,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":609,"NA":611},{"trials":598,"activeCount":50},[],{"trials":600,"activeCount":50},[],{"trials":602,"activeCount":50},[],{"trials":604,"activeCount":50},[605],{"nctId":260,"briefTitle":261,"status":230,"phases":606,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":607,"interventions":608},[42],[29],[173,268,225],{"trials":610,"activeCount":50},[],{"trials":612,"activeCount":50},[],{"intervention":614,"totalTrials":8,"cells":615},"becatecarin",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":635,"NA":637},{"trials":617,"activeCount":50},[],{"trials":619,"activeCount":50},[],{"trials":621,"activeCount":50},[],{"trials":623,"activeCount":50},[624],{"nctId":625,"briefTitle":626,"status":230,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT00090025","XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors",[42],"2006-11","2004-09",248,[632],"Biliary Tract Cancer",[614,634],"5-Fluorouracil Plus Leucovorin",{"trials":636,"activeCount":50},[],{"trials":638,"activeCount":50},[],{"intervention":634,"totalTrials":8,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":653,"NA":655},{"trials":642,"activeCount":50},[],{"trials":644,"activeCount":50},[],{"trials":646,"activeCount":50},[],{"trials":648,"activeCount":50},[649],{"nctId":625,"briefTitle":626,"status":230,"phases":650,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":651,"interventions":652},[42],[632],[614,634],{"trials":654,"activeCount":50},[],{"trials":656,"activeCount":50},[],{"intervention":658,"totalTrials":8,"cells":659},"Anamorelin Hydrochloride",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":675,"NA":677},{"trials":661,"activeCount":50},[],{"trials":663,"activeCount":50},[],{"trials":665,"activeCount":50},[],{"trials":667,"activeCount":50},[668],{"nctId":669,"briefTitle":566,"status":125,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":570,"conditions":673,"interventions":674},"NCT03743051",[42],"2023-02-11","2019-03-05",[25,27],[658],{"trials":676,"activeCount":50},[],{"trials":678,"activeCount":50},[],{"intervention":411,"totalTrials":8,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":693,"NA":695},{"trials":682,"activeCount":50},[],{"trials":684,"activeCount":50},[],{"trials":686,"activeCount":50},[],{"trials":688,"activeCount":50},[689],{"nctId":405,"briefTitle":406,"status":125,"phases":690,"primaryCompletion":334,"completion":334,"start":301,"enrollment":408,"conditions":691,"interventions":692},[42],[15],[411,412,307],{"trials":694,"activeCount":50},[],{"trials":696,"activeCount":50},[],{"intervention":412,"totalTrials":8,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":711,"NA":713},{"trials":700,"activeCount":50},[],{"trials":702,"activeCount":50},[],{"trials":704,"activeCount":50},[],{"trials":706,"activeCount":50},[707],{"nctId":405,"briefTitle":406,"status":125,"phases":708,"primaryCompletion":334,"completion":334,"start":301,"enrollment":408,"conditions":709,"interventions":710},[42],[15],[411,412,307],{"trials":712,"activeCount":50},[],{"trials":714,"activeCount":50},[],{"intervention":716,"totalTrials":21,"cells":717},"Elsiglutide",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":719,"activeCount":50},[],{"trials":721,"activeCount":50},[],{"trials":723,"activeCount":50},[724,734],{"nctId":725,"briefTitle":726,"status":125,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":733},"NCT02383810","Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)",[41],"2016-02","2015-01",498,[732],"Drug and\u002For Toxin-induced Diarrhea",[716],{"nctId":735,"briefTitle":736,"status":125,"phases":737,"primaryCompletion":738,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT01543451","Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea",[41],"2013-01","2013-10","2012-02",138,[743],"Diarrhea",[716],{"trials":746,"activeCount":50},[],{"trials":748,"activeCount":50},[],{"trials":750,"activeCount":50},[],{"intervention":293,"totalTrials":8,"cells":752},{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":754,"activeCount":50},[],{"trials":756,"activeCount":50},[],{"trials":758,"activeCount":50},[759],{"nctId":284,"briefTitle":285,"status":125,"phases":760,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":761,"interventions":762},[41],[291],[293,274,293,274],{"trials":764,"activeCount":50},[],{"trials":766,"activeCount":50},[],{"trials":768,"activeCount":50},[],{"intervention":770,"totalTrials":8,"cells":771},"Infigratinib",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":773,"activeCount":50},[],{"trials":775,"activeCount":50},[],{"trials":777,"activeCount":50},[778],{"nctId":779,"briefTitle":780,"status":781,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":50,"conditions":785,"interventions":789},"NCT05222165","Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations","WITHDRAWN",[40,41],"2022-12-16","2021-10-01",[786,787,788],"Advanced Solid Tumor","CNS Tumor","Recurrent WHO Grade II Glioma",[770],{"trials":791,"activeCount":50},[],{"trials":793,"activeCount":50},[],{"trials":795,"activeCount":50},[],{"intervention":226,"totalTrials":8,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":808,"PHASE4":810,"NA":812},{"trials":799,"activeCount":50},[],{"trials":801,"activeCount":50},[],{"trials":803,"activeCount":50},[804],{"nctId":215,"briefTitle":216,"status":125,"phases":805,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":806,"interventions":807},[41],[31,223],[189,225,226],{"trials":809,"activeCount":50},[],{"trials":811,"activeCount":50},[],{"trials":813,"activeCount":50},[],{"intervention":815,"totalTrials":8,"cells":816},"Fosnetupitant 235 mg solution",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":818,"activeCount":50},[],{"trials":820,"activeCount":50},[821],{"nctId":822,"briefTitle":823,"status":230,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":254,"conditions":828,"interventions":829},"NCT06840769","A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers",[40],"2023-10-18","2023-10-23","2023-06-17",[18],[815,830],"Akynzeo solution",{"trials":832,"activeCount":50},[],{"trials":834,"activeCount":50},[],{"trials":836,"activeCount":50},[],{"trials":838,"activeCount":50},[],{"intervention":830,"totalTrials":8,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":842,"activeCount":50},[],{"trials":844,"activeCount":50},[845],{"nctId":822,"briefTitle":823,"status":230,"phases":846,"primaryCompletion":825,"completion":826,"start":827,"enrollment":254,"conditions":847,"interventions":848},[40],[18],[815,830],{"trials":850,"activeCount":50},[],{"trials":852,"activeCount":50},[],{"trials":854,"activeCount":50},[],{"trials":856,"activeCount":50},[],{"intervention":210,"totalTrials":8,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":860,"activeCount":50},[],{"trials":862,"activeCount":50},[863],{"nctId":202,"briefTitle":203,"status":125,"phases":864,"primaryCompletion":205,"completion":206,"start":207,"enrollment":6,"conditions":865,"interventions":866},[40],[18,187],[173,210,211],{"trials":868,"activeCount":50},[],{"trials":870,"activeCount":50},[],{"trials":872,"activeCount":50},[],{"trials":874,"activeCount":50},[],{"intervention":211,"totalTrials":8,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":878,"activeCount":50},[],{"trials":880,"activeCount":50},[881],{"nctId":202,"briefTitle":203,"status":125,"phases":882,"primaryCompletion":205,"completion":206,"start":207,"enrollment":6,"conditions":883,"interventions":884},[40],[18,187],[173,210,211],{"trials":886,"activeCount":50},[],{"trials":888,"activeCount":50},[],{"trials":890,"activeCount":50},[],{"trials":892,"activeCount":50},[]]